UNION CITY, Calif.,
Oct. 28, 2016 /PRNewswire/ -- The
Board of Directors of Abaxis, Inc. (NasdaqGS: ABAX), has declared a
cash dividend of $0.14 per common
share. The dividend will be payable on December 15, 2016 to all shareholders of record
at the close of business on December
1, 2016. Abaxis increased the dividend by
approximately 17%, to $0.14 from its
prior quarterly cash dividend of $0.12 per share. Any future dividends will
be subject to approval by Abaxis' Board of Directors.
"Today's announcement reflects our commitment to enhancing
shareholder value and our confidence in the company's long term
cash flows," said Clint Severson,
chairman and chief executive officer of Abaxis. "As always,
we are focused on and committed to using our cash to invest for
future growth and delivering shareholder value."
About Abaxis
Abaxis, Inc. is a worldwide developer, manufacturer and marketer
of portable blood analysis systems that are used in a broad range
of medical specialties in human or veterinary patient care to
provide clinicians with rapid blood constituent measurements.
Our mission is to improve the efficiency of care delivery to and
the quality of life of patients in the medical and veterinary
markets. We provide leading edge technology and tools that
support best medical practices, enabling physicians and
veterinarians to respond to the health needs of their clients at
the point of care while operating economical and profitable
practices. For more information, visit
http://www.abaxis.com.
Forward-Looking Statements
This press release includes statements that constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Reform Act"),
including but not limited to statements related to payment of
future cash dividends, Abaxis' long-term cash flows, Abaxis' use of
cash to invest for future growth and Abaxis' performance in future
periods and ability to deliver shareholder value. Abaxis
claims the protection of the safe-harbor for forward-looking
statements contained in the Reform Act. These forward-looking
statements are often characterized by the terms "may," "believes,"
"projects," "expects," "anticipates," or words of similar import,
and do not reflect historical facts. Specific forward-looking
statements contained in this press release may be affected by risks
and uncertainties, including, but not limited to, those related to
risks related to Abaxis' manufacturing operations, including the
vulnerability of its manufacturing operations to potential
interruptions and delays and its ability to manufacture products
free of defects, Abaxis' ability to compete effectively, market
acceptance of Abaxis' products, fluctuations in quarterly operating
results and difficulty in predicting future results, the
performance of Abaxis' independent distributors and Abaxis' ability
to manage their inventory levels effectively, expansion of Abaxis'
sales and marketing and distribution efforts, Abaxis' dependence on
Abbott Point of Care, Inc. for its U.S. medical sales, dependence
on sole or limited source suppliers, the effect of exchange rate
fluctuations on international operations, dependence on key
personnel, risks related to the protection of Abaxis' intellectual
property or claims of infringement of intellectual property
asserted by third parties. Readers should also refer to the
section entitled "Risk Factors" in Abaxis' Annual Report on Form
10‑K, and subsequently filed quarterly reports on Form 10‑Q filed
with the United States Securities and Exchange Commission.
Forward-looking statements speak only as of the date the statements
were made. Abaxis does not undertake and specifically
disclaims any obligation to update any forward-looking
statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abaxis-declares-quarterly-cash-dividend-300353282.html
SOURCE Abaxis, Inc.